Jaiswal, V., Hanif, M., Mashkoor, Y., Jaiswal, A., Prasad, T., Rajak, K., … Fonarow, G. C. (2024). Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv, 3(12), 101405. https://doi.org/10.1016/j.jacadv.2024.101405

Jaiswal, Vikash, Muhammad Hanif, Yusra Mashkoor, Akash Jaiswal, Tanisha Prasad, Kripa Rajak, Muhammad Shahzeb Khan, Robert J. Mentz, and Gregg C. Fonarow. “Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy.” JACC Adv 3, no. 12 (December 2024): 101405. https://doi.org/10.1016/j.jacadv.2024.101405.

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Dec;3(12):101405.

Jaiswal, Vikash, et al. “Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy.” JACC Adv, vol. 3, no. 12, Dec. 2024, p. 101405. Pubmed, doi:10.1016/j.jacadv.2024.101405.

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Dec;3(12):101405.